FDA launch plan to tackle e-cig epidemic
pharmafile | September 14, 2018 | News story | Medical Communications | FDA, Scott Gottlieb, USA, e-cig, juul
The FDA have announced a plan to crack down on the so-called ‘e-cig epidemic’, following revelations that vaping and use of e-cigarettes has become widespread among school aged American teenagers.
FDA commissioner Scott Gottlieb was forthright in suggesting that e-cigarette use had reached crisis level proportions as he said in a statement that: “Unfortunately, I now have good reason to believe that it’s reached nothing short of an epidemic proportion of growth.”
His plan, which aims to tackle the growing frequency with which e-cigarettes are used among young people in the United States, began in sending “1,100 warning letters to stores for the illegal sale of e-cigarettes to minors” as well as “131 civil money penalties to stores that continued to violate the restrictions on sales to minors.”
The FDA commissioner continued in noting “We’re especially focused on the flavored e-cigarettes. And we’re seriously considering a policy change that would lead to the immediate removal of these flavored products from the market.”
In addressing the problem directly however, Gottlieb commented: “Today, we sent letters to five e-cigarette manufacturers whose products were sold to kids during the enforcement blitz and that, collectively, represent more than 97 percent of the current market for e-cigs — JUUL, Vuse, MarkTen, blu e-cigs, and Logic. These brands will be the initial focus of our attention when it comes to protecting kids.
Given the magnitude of the problem, we’re requesting that the manufacturers of these brands and products come back to the FDA in 60 days with robust plans on how they’ll convincingly address the widespread use of their products by minors, or we’ll revisit the FDA’s exercise of enforcement discretion for products currently on the market.”
Louis Goss
Related Content
MRM Health’s ulcerative colitis treatment receives FDA Investigational New Drug clearance
Microbial Resource Management (MRM) Health has announced that its lead programme, MH002, has received Investigational …
Complement Therapeutics’ geographic atrophy treatment receives FDA Fast Track designation
Complement Therapeutics has announced that CTx001, its gene therapy treatment for geographic atrophy (GA) secondary …
Johnson & Johnson submits robotic surgical system for De Novo classification
Johnson & Johnson has announced the submission of its Ottava Robotic Surgical System for De …
